12:00 AM
 | 
Aug 14, 2000
 |  BC Week In Review  |  Company News  |  Deals

Avanir Pharmaceuticals, Irisys Research and Development LLC deal

Irisys granted AVN a worldwide exclusive license to AVP-923, which combines the NMDA receptor antagonist dextromethorphan (a marketed drug) with an enzyme...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >